The circulating level of MMP-9 and its ratio to TIMP-1 as a predictor of severity in patients with community-acquired pneumonia

Clinica Chimica Acta

Volumn 424, Issue , 2013, Pages 261-266

  Chiang, Ting Yen ^a   Yu, Yung Luen ^b,c   Lin, Chiao Wen ^a   Tsao, Shih Ming ^a,d   Yang, Shun Fa ^a,d   Yeh, Chao Bin ^a,d  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Community acquired pneumonia; Gene polymorphism; MMP 9; TIMP 1

Indexed keywords

ANTIBIOTIC AGENT; CYTOSINE; GELATINASE B; THYMINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; APACHE; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; GELATINASE B BLOOD LEVEL; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN CELL; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RESPIRATORY TRACT PARAMETERS; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE INHIBITOR OF METALLOPROTEINASE 1 BLOOD LEVEL;

COMMUNITY-ACQUIRED PNEUMONIA; GENE POLYMORPHISM; MMP-9; TIMP-1;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; DISEASE SUSCEPTIBILITY; FEMALE; GENE EXPRESSION; HUMANS; LENGTH OF STAY; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PNEUMONIA, BACTERIAL; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1; UP-REGULATION;

EID: 84880448183     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.06.013     Document Type: Article

References (35)

1. Cheng C.W., Chien M.H., Su S.C., Yang S.F. New markers in pneumonia. Clin Chim Acta 2013, 419C:19-25.
2. Lin C.C., Lee C.H., Chen C.Z., et al. Value of the pneumonia severity index in assessment of community-acquired pneumonia. J Formos Med Assoc 2005, 104:164-167.
3. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382.
4. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
5. Atkinson J.J., Senior R.M. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003, 28:12-24.
6. Klein T., Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011, 41:271-290.
7. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115:3719-3727.
8. Higashimoto Y., Yamagata Y., Iwata T., et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J 2005, 25:885-890.
9. Yang S.F., Chu S.C., Chiang I.C., et al. Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia. Clin Chim Acta 2005, 352:209-215.
10. Chiang T.Y., Shyu L.Y., Tsao T.C., et al. Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia. Clin Chem Lab Med 2012, 50:449-454.
11. Mühl D., Nagy B., Woth G., et al. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. J Crit Care 2011, 26:550-555.
12. Sanders J.S., Huitema M.G., Hanemaaijer R., et al. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. Am J Physiol Renal Physiol 2007, 293:F1927-F1934.
13. Chua P.K., Melish M.E., Yu Q., et al. Elevated concentrations of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Clin Diagn Lab Immunol 2003, 10:308-314.
14. Yi Y.C., Chen M.K., Chen L.Y., et al. Genetic polymorphism of the tissue inhibitor of metalloproteinase-1 is associated with an increased risk of endometrial cancer. Clin Chim Acta 2009, 409:127-131.
15. Wei J.C., Lee H.S., Chen W.C., Shiu L.J., Yang S.F., Wong R.H. Genetic polymorphisms of the matrix metalloproteinase-3 (MMP-3) and tissue inhibitors of matrix metalloproteinases-1 (TIMP-1) modulate the development of ankylosing spondylitis. Ann Rheum Dis 2009, 68:1781-1786.
16. Meijer M.J., Mieremet-Ooms M.A., van Hogezand R.A., Lamers C.B., Hommes D.W., Verspaget H.W. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 2007, 13:2960-2966.
17. Hung K.H., Hung H.W., Yang H.B., Lu C.C., Wu J.J., Sheu B.S. Host single nucleotide polymorphisms of MMP-9-1562/TIMP-1 372 have gender differences in the risk of gastric intestinal metaplasia after Helicobacter pylori infection. Helicobacter 2009, 14:580-587.
18. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72.
19. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
20. Johnatty R.N., Taub D.D., Reeder S.P., et al. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 1997, 158:2327-2333.
21. Worthmann H., Tryc A.B., Goldbecker A., et al. The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis 2010, 30:85-92.
22. Susskind H., Hymowitz M.H., Lau Y.H., et al. Increased plasma concentrations of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys 2003, 56:1161-1169.
23. Vignola A.M., Riccobono L., Mirabella A., et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998, 158:1945-1950.
24. Goleva E., Hauk P.J., Boguniewicz J., Martin R.J., Leung D.Y. Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. J Allergy Clin Immunol 2007, 120:1065-1072.
25. Moore C.S., Crocker S.J. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 2012, 180:12-16.
26. Olafsdóttir I.S., Janson C., Lind L., Hulthe J., Gunnbjörnsdóttir M., Sundström J. Serum concentrations of matrix metalloproteinase-9, tissue inhibitors of metalloproteinase-1 and their ratio are associated with impaired lung function in the elderly: a population-based study. Respirology 2010, 15:530-535.
27. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. N Engl J Med 1995, 333:1618-1624.
28. Pereira J.M., Paiva J.A., Rello J. Assessing severity of patients with community-acquired pneumonia. Semin Respir Crit Care Med 2012, 33:272-283.
29. Singanayagam A., Chalmers J.D., Hill A.T. Severity assessment in community-acquired pneumonia: a review. QJM 2009, 102:379-388.
30. Docherty A.J., Lyons A., Smith B.J., et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985, 318:66-69.
31. Hinterseher I., Krex D., Kuhlisch E., et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphisms in a Caucasian population with abdominal aortic aneurysm. World J Surg 2007, 31:2248-2254.
32. Skarmoutsou E., D'Amico F., Marchini M., Malaponte G., Scorza R., Mazzarino M.C. Association of TIMP-1 +372 SNP with digital ulcer manifestation in female systemic sclerosis patients. Hum Immunol 2012, 73:950-953.
33. Meijer M.J., Mieremet-Ooms M.A., Sier C.F., et al. Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in Crohn's disease. Inflamm Bowel Dis 2009, 15:84-92.
34. Kernacki K.A., Goebel D.J., Poosch M.S., Hazlett L.D. Early TIMP gene expression after corneal infection with Pseudomonas aeruginosa. Invest Ophthalmol Vis Sci 1998, 39:331-335.
35. Schaaf B., Liebau C., Kurowski V., Droemann D., Dalhoff K. Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteinase activity. BMC Pulm Med 2008, 8:12.